

Next Edge Biotech and Life Sciences Opportunities Fund
 Quarterly Summary of Investment Portfolio as at March 31, 2024



Portfolio by Asset Mix	% of Net Asset Value	
	Long	Short
United States Equity	65.8	-
Foreign Equity	11.8	-
Equity Options	7.7	(0.2)
Canadian Equity	6.9	-
Canadian Bond	2.5	-
United States Bond	1.3	-
	96.0	(0.2)
Cash and Cash Equivalents	4.0	-
Other Net Assets (Liabilities)	0.2	-
	100.2	(0.2)

Portfolio by Sector	% of Net Asset Value	
	Long	Short
Pharmaceuticals, Biotechnology & Life Sciences	68.6	-
Health Care Equipment & Services	19.7	-
Equity Options	7.7	(0.2)
	96.0	(0.2)
Cash and Cash Equivalents	4.0	-
Other Net Assets (Liabilities)	0.2	-
	100.2	(0.2)

Portfolio by Geography	% of Net Asset Value	
	Long	Short
United States	74.8	(0.2)
International	11.8	-
Canada	9.4	-
	96.0	(0.2)
Cash and Cash Equivalents	4.0	-
Other Net Assets (Liabilities)	0.2	-
	100.2	(0.2)

Next Edge Biotech and Life Sciences Opportunities Fund
 Quarterly Summary of Investment Portfolio as at March 31, 2024



Top 25 Long Positions¹	% of Net Asset Value
Verona Pharma PLC, ADR	4.1
Cash and cash equivalents	4.0
Nektar Therapeutics	3.7
Cytokinetics Inc.	3.4
10X Genomics Inc.	3.4
Phathom Pharmaceuticals Inc.	3.2
Schrodinger Inc.	3.2
Reviva Pharmaceuticals Holdings Inc.	3.1
TG Therapeutics Inc.	3.0
Pacific Biosciences of California Inc.	3.0
CRISPR Therapeutics AG	3.0
Delcath Systems Inc.	2.8
Collectar Biosciences Inc.	2.8
Protalix BioTherapeutics Inc.	2.7
Imagin Medical Inc., Private Bond, September 30, 2024	2.5
Eledon Pharmaceuticals Inc.	2.5
Neuraxis Inc.	2.4
Exscientia PLC, ADR	2.4
Personalis Inc.	2.4
MeiraGTx Holdings PLC	2.3
Immix Biopharma Inc.	2.3
Fennec Pharmaceuticals Inc.	2.2
ClearPoint Neuro Inc.	2.2
Microbix Biosystems Inc.	2.1
Simulations Plus Inc.	1.9

Top 2 Short Positions¹	% of Net Asset Value
ACTINIUM PHARMACEUTICALS@12.5 CALL OPT 16 AUG 24	(0.2)
ANNOVIS BIO INC@32.5 CALL OPT 19 APR 24	-

Net Asset Value of Next Edge Biotech and Life Sciences Opportunities Fund as at March 31, 2024 **\$10,253,299**

1. There are no other short positions as at March 31, 2024